Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting-Reference-Cited by-同舟云学术

Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting

Published:2021-11-09 Issue:21 Volume:5 Page:4500-4503
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Marzolini Maria A. V.¹²^ORCID,Mehra Varun³^ORCID,Thomson Kirsty J.²,Tholouli Eleni⁴,Bloor Adrian J. C.⁵^ORCID,Parker Anne⁶^ORCID,Lovell Richard⁷,Orchard Kim⁸^ORCID,Publicover Amy⁹,Nicholson Emma¹⁰^ORCID,Snowden John A.¹¹^ORCID,Byrne Jennifer¹²,Khan Anjum¹³^ORCID,Gilleece Maria H.¹³,Errico Gerardo¹²,Lozano Sara¹⁰,Hurst Erin⁹,Duncan Nick⁷^ORCID,Pirrie Jennifer⁶,Crea Philip⁴,Carpenter Ben²^ORCID,Pagliuca Antonio³,Peggs Karl S.¹²

Affiliation:

1. Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom;

2. Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom;

3. Department of Haematology, Kings College Hospital, London, United Kingdom;

4. Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom;

5. Department of Haematology, The Christie NHS Foundation Trust, Manchester, United Kingdom;

6. Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom;

7. Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;

8. Department of Haematology, University Hospital Southampton, Southampton, United Kingdom;

9. Department of Haematology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom;

10. Department of Haematology, The Royal Marsden NHS Foundation Trust, London, United Kingdom;

11. Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom;

12. Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; and

13. Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/5/21/4500/1833017/advancesadv2021005637.pdf

Reference5 articles.

1. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation;Zamora;Blood.,2021

2. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease;Reusser;Blood.,1991

3. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation;Marty;N Engl J Med.,2017

4. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution;Chakrabarti;Blood.,2002

5. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival;Juliusson;Bone Marrow Transplant.,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre‐emptive monitoring in the era of letermovir;Transplant Infectious Disease;2023-10-20

2. High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience;Bone Marrow Transplantation;2023-08-23

3. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: A narrative review;Journal of Medical Virology;2023-08

4. Features of cytomegalovirus DNAemia and virus‐specific T‐cell responses in allogeneic hematopoietic stem‐cell transplant recipients during prophylaxis with letermovir;Transplant Infectious Disease;2023-02-07

5. Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus‐specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis;American Journal of Hematology;2023-01-11